BrightSpring Health price target raised to $42 from $35 at UBS

UBS raised the firm’s price target on BrightSpring Health (BTSG) to $42 from $35 and keeps a Buy rating on the shares. BrightSpring’s Q3 results were positive with another beat and raise quarter, with management expressing optimism around this momentum continuing into 2026, with a particular emphasis on the growth prospects within its infusion business, the analyst tells investors in a research note.